In This Section


Please Note:  All session times for the AACR Special Conference: Ovarian Cancer are U.S. Eastern Time (ET). 

Tuesday, September 14

Plenary Session 1: Epidemiology and Cancer Prevention 
10-11:40 a.m.   
Session Chair: Elizabeth M. Swisher, University of Washington, Seattle, Washington 

Opportunistic salpingectomy: One decade later 
Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada 

Ovarian cancer detection and risk assessment using high fidelity sequencing 
Rosana Risques, University of Washington, Seattle, Washington

PALB2, ovarian cancer gene?
Barbara Norquist, University of Washington, Seattle, Washington

Endometriosis and ovarian cancer risk
Holly Harris, Fred Hutchinson Cancer Center, Seattle, Washington 

Panel Discussion 

11:40-11:55 a.m.
Plenary Session 2: Ovarian Cancer Genetics, Epigenetics, and Evolution 
11:55 a.m.-1:35 p.m.   
Session Chair: Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, New York 

Longitudinal, multi-region assessment of tumor evolution in patients with high-grade serous ovarian cancer
Sampsa Hautaniemi, University of Helsinki, Helsinki, Finland

Rewiring of transcriptional circuits during high-grade serous ovarian cancer development 
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, California

Genomic and immunological features of high-grade serous ovarian cancer in long-term survivors
Dale W. Garsed, Peter MacCallum Cancer Centre, Melbourne, Australia

Panel Discussion 

Wednesday, September 15

Plenary Session 3: DNA Damage and Replication Stress 
10-11:40 a.m.    
Session Chair: Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois 

Overcoming PARP inhibitor resistance
Alan D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts

USP1-trapping lesions as a source of DNA replication stress and genomic instability 
Tony Huang, NYU Langone Health Perlmutter Cancer Center, New York, New York  

The role of BRCA1 mutations in promoting therapy resistance
Neil Johnson, Fox Chase Cancer Center, Philadelphia, Pennsylvania

The success and challenges of introducing PARP inhibitors into the therapy of ovarian cancer
Jonathan A. Ledermann, UCL Cancer Institute at University College London, London, United Kingdom

Panel Discussion 

11:40-11:55 a.m.
Plenary Session 4: Immunology and Tumor Microenvironment 
11:55 a.m.-1:35 p.m.  
Session Chair: Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England

Single-cell spatial proteomic profiling of the tumor microenviroment for biomarker discovery in ovarian cancer
Anniina Färkkilä, University of Helsinki, Helsinki, Finland 

Engineering adoptive T cell therapy to overcome immune suppression in ovarian cancer 
Kristin G. Anderson, Fred Hutchinson Cancer Center, Seattle, Washington

Mechanisms of tumor immunogenicity and anti-tumor immunity in ovarian cancer
Denarda Dangaj, Ludwig Institute for Cancer Research UNIL CHUV, Lausanne, Switzerland

Mutational processes as determinants of immunophenotypes in ovarian cancer
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion